Core Viewpoint - Shenzhen Hanyu Pharmaceutical Co., Ltd. (hereinafter referred to as "Hanyu Pharmaceutical") expects significant revenue growth in 2025, with projected revenue between 950 million to 980 million yuan, representing an increase of 60.96% to 66.05% year-on-year, and a net profit of 40 million to 50 million yuan, marking a turnaround from losses in the previous year [1] Group 1: Financial Performance - The company anticipates 2025 revenue of 950 million to 980 million yuan, a year-on-year growth of 60.96% to 66.05% [1] - Net profit is projected to be between 40 million to 50 million yuan, indicating a return to profitability [1] Group 2: Business Development - The growth in revenue is driven by the synergy between international formulations and active pharmaceutical ingredients, which are core engines of revenue growth [1] - The CRDMO (Contract Research, Development, and Manufacturing Organization) business is being actively advanced, contributing to the company's growth strategy [1] Group 3: Research and Innovation - Hanyu Pharmaceutical maintains a strong focus on innovation, with high R&D investment aimed at developing peptide innovative drugs, complex formulations, and cutting-edge technology platforms [1] - Significant progress has been made in multiple research projects, including the three-target innovative drug HY3003 and semaglutide, reinforcing the company's technological barriers [1] Group 4: Strategic Partnerships - The company is expanding its growth avenues through CRDMO business, leveraging its multi-national GMP certification and full industry chain capabilities [1] - Collaborations with companies like Carbon Cloud Peptide and Borui Pharmaceutical have been deepened, covering projects in areas such as antimicrobial peptides and oral peptides, successfully transforming technical accumulation into systematic service output capabilities [1]

Core Viewpoint - Zhejiang Haizheng Pharmaceutical and Zhejiang Shengzhao Pharmaceutical announced a joint investment of 2.3 billion yuan to establish a joint venture aimed at the high-end complex formulation international market, marking a new chapter in the globalization of China's complex formulations [1][4]. Group 1: Joint Venture and Market Strategy - The joint venture targets the high-end complex formulation market, which is known for its technical and production challenges [2]. - Shengzhao Pharmaceutical has successfully developed six technology platforms and has products approved for market, indicating a concentrated harvest period for its R&D efforts [2][3]. - Haizheng Pharmaceutical has a mature commercial system and international export platform, which will support the joint venture's growth [3]. Group 2: Production Challenges and Solutions - Shengzhao Pharmaceutical has faced challenges in scaling production, traditionally relying on CMO models, which could delay market entry [2][3]. - The joint venture aims to overcome these challenges by leveraging Haizheng's manufacturing capabilities and Shengzhao's R&D strengths [3][4]. - The new production technology developed by Shengzhao will allow for batch production every 5-7 days, significantly increasing output and reducing costs [5][6]. Group 3: Future Plans and Market Potential - The joint venture plans to register by the end of the year, begin construction in 2026, and aim for the first product approval by 2030 [8]. - The global complex injection market is projected to reach a scale of 100 billion USD by 2030, with China's market expected to grow to 77.9 billion yuan by 2030 [8][9]. - The strategy includes launching mature products in international markets first, followed by the development of improved drugs [9][10]. Group 4: Innovation and Clinical Relevance - The focus of the joint venture will be on developing innovative formulations that address clinical needs rather than merely changing dosage forms [10]. - The collaboration aims to set a benchmark for high-end manufacturing in China and establish a leading position in the global complex formulation market [7][10].